US genomic services specialist Cogenics has launched a new DMET analysis service that it believes will improve patient genotyping during clinical trials, helping drug industry sponsors target the development of new products and reduce costs.
Canadian CRO MDS Pharma Services (MDS) is to sell its Phase II-IV trial business to US counterpart INC Research for $50m (€35m) and focus on providing discovery and early clinical development services.
UK CRO Quotient Bioresearch has bought a clinical research facility in Edinburgh, Scotland, which in conjunction with an existing unit in Nottingham, England will serve as a base for its new Quotient Clinical unit.
BerGenBio is at BIO 2009 presenting its CellSelectRNAi technology and other services, which in the four months the company has been operational have landed it a multi-million dollar deal with a "big blue-chip pharma".
CRO Encorium has unveiled plans to sell both its US business and its Finnish subsidiary Encorium Oy just weeks after posting a gloomy set of Q1 financials dominated by a 15 per cent drop in net revenues.